ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0882

Coexistence of ANCA-Associated Vasculitis and Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: A Diagnostic and Treatment Dilemma

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Ortiz, Melina J, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Astorga, Nestor Gerardo, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Alrahamneh, Hebah, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Kanduri, Swetha Rani, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Introduction

Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), is a manifestation of monoclonal gammopathy of renal significance (MGRS), characterized by monoclonal immunoglobulin deposition, most commonly IgG3 kappa in the glomeruli. In contrast, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a pauci-immune small-vessel vasculitis with minimal immune complex deposition. Their coexistence is exceptionally rare and presents a diagnostic and therapeutic challenge.

Case Description

A 63-year-old Hispanic male presented with a 3-month history of hemoptysis, 15-pound unintentional weight loss and a non-blanching maculopapular rash. Physical examination revealed tongue ulcers, swollen joints, and bilateral skin lesions. Laboratory tests showed PR3-ANCA >8 U/mL, positive rheumatoid factor, serum creatinine 0.74 mg/dL. Urinalysis showed 3+ blood and 1+ protein with a urine protein-to-creatinine ratio of 1 g/g. Serum protein electrophoresis revealed polyclonal gammopathy without a monoclonal spike; serum myeloperoxidase was negative. Renal biopsy was performed. Light microscopy demonstrated focal segmental necrotizing and crescentic glomerulonephritis, consistent with AAV. Immunofluorescence revealed mesangial IgG3 κ-restricted granular electron-dense deposits and mesangial hypercellularity consistent with PGNMID. Absence of a detectable peripheral clone further complicated the treatment approach. Induction therapy with IV methylprednisolone and rituximab was initiated, followed by oral prednisone taper. The patient showed symptomatic improvement with declining PR3 titers and reduction in proteinuria.

Discussion

This case illustrates a rare and diagnostically challenging overlap between PGNMID and AAV. The precise pathophysiological relationship between these entities remains unclear—whether they arise from distinct mechanisms or reflect a shared underlying immune dysregulation. Currently, there are no established guidelines for the management of coexisting PGNMID and AAV. Given the rarity and clinical complexity of this presentation, further research is essential to elucidate the underlying mechanisms to develop evidence-based therapeutic strategies.

Digital Object Identifier (DOI)